Shaun McNulty
Directeur Technique/Scientifique/R&D chez Awakn Life Sciences, Inc.
Postes actifs de Shaun McNulty
Sociétés | Poste | Début | Fin |
---|---|---|---|
Awakn Life Sciences, Inc.
Awakn Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology AWAKN Life Sciences, Inc. provides evidence-based psychedelic assisted psychotherapy solutions. The company is headquartered in Toronto, Canada. | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Shaun McNulty
Anciens postes connus de Shaun McNulty
Sociétés | Poste | Début | Fin |
---|---|---|---|
AWAKN LIFE SCIENCES CORP. | Directeur Technique/Scientifique/R&D | - | 01/09/2023 |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Directeur Technique/Scientifique/R&D | - | - |
Inflection Biosciences Ltd.
Inflection Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Inflection Biosciences Ltd. is an Irish drug development company that focuses on discovering and developing small molecule therapeutics to address major unmet needs in cancer, autoimmune, and inflammatory diseases. Inflection Biosciences is based in Blackrock, IE. The private company's pipeline includes IBL-202, a first-in-class dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML, and multiple myeloma, and the IBL-100 series, which comprises selective pan-PIM kinase inhibitors. The partnered pipeline includes AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Shaun McNulty
The University of York | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 3 |
Canada | 3 |
Irlande | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
AWAKN LIFE SCIENCES CORP. | Health Services |
Entreprise privées | 3 |
---|---|
Inflection Biosciences Ltd.
Inflection Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Inflection Biosciences Ltd. is an Irish drug development company that focuses on discovering and developing small molecule therapeutics to address major unmet needs in cancer, autoimmune, and inflammatory diseases. Inflection Biosciences is based in Blackrock, IE. The private company's pipeline includes IBL-202, a first-in-class dual PIM kinase and PI3K inhibitor in development for B-cell malignancies, AML, and multiple myeloma, and the IBL-100 series, which comprises selective pan-PIM kinase inhibitors. The partnered pipeline includes AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. | Health Technology |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
Awakn Life Sciences, Inc.
Awakn Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology AWAKN Life Sciences, Inc. provides evidence-based psychedelic assisted psychotherapy solutions. The company is headquartered in Toronto, Canada. | Health Technology |
- Bourse
- Insiders
- Shaun McNulty
- Expérience